Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease

NCT03459079 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

128

Enrollment

OTHER

Sponsor class

Conditions

Nonalcoholic Fatty Liver Disease (NAFLD)
Type 2 Diabetes (T2DM)

Interventions

DRUG: Lanifibranor
OTHER: Placebo

Sponsor

University of Florida

Collaborators

[object Object]